Cytosorbents (NASDAQ:CTSO) Given Buy Rating at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Cytosorbents (NASDAQ:CTSO) in a report issued on Tuesday morning,Benzinga reports. The brokerage currently has a $10.00 target price on the medical research company’s stock.

Separately, StockNews.com assumed coverage on shares of Cytosorbents in a research report on Wednesday, March 26th. They set a “hold” rating for the company. Two investment analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Cytosorbents presently has an average rating of “Moderate Buy” and a consensus price target of $4.67.

Cytosorbents Stock Performance

Shares of NASDAQ:CTSO opened at $1.00 on Tuesday. The firm has a 50 day moving average of $1.07 and a 200 day moving average of $1.05. The company has a quick ratio of 1.58, a current ratio of 1.97 and a debt-to-equity ratio of 1.06. The company has a market capitalization of $54.68 million, a price-to-earnings ratio of -2.78 and a beta of 0.78. Cytosorbents has a 52 week low of $0.70 and a 52 week high of $1.61.

Cytosorbents (NASDAQ:CTSO) last announced its quarterly earnings results on Monday, March 31st. The medical research company reported ($0.03) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.04. The business had revenue of $9.20 million for the quarter, compared to the consensus estimate of $10.09 million. Cytosorbents had a negative return on equity of 118.54% and a negative net margin of 49.47%. On average, sell-side analysts predict that Cytosorbents will post -0.3 earnings per share for the current fiscal year.

Institutional Trading of Cytosorbents

Institutional investors have recently made changes to their positions in the business. Millennium Management LLC purchased a new stake in Cytosorbents in the fourth quarter valued at about $30,000. Renaissance Technologies LLC increased its holdings in shares of Cytosorbents by 10.6% during the fourth quarter. Renaissance Technologies LLC now owns 88,020 shares of the medical research company’s stock valued at $80,000 after acquiring an additional 8,400 shares in the last quarter. Northern Trust Corp raised its position in shares of Cytosorbents by 22.3% in the 4th quarter. Northern Trust Corp now owns 91,560 shares of the medical research company’s stock valued at $83,000 after purchasing an additional 16,701 shares during the last quarter. Raymond James Financial Inc. purchased a new position in shares of Cytosorbents in the 4th quarter valued at approximately $99,000. Finally, Geode Capital Management LLC boosted its stake in Cytosorbents by 7.5% in the 3rd quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock worth $701,000 after purchasing an additional 32,415 shares in the last quarter. Institutional investors and hedge funds own 32.87% of the company’s stock.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.